​

Krystal Biotech (KRYS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KRYS Stock Forecast

Krystal Biotech (KRYS) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $326.20, with a high of $371.00 and a low of $300.00. This represents a 4.41% increase from the last price of $312.41.

$100 $160 $220 $280 $340 $400 High: $371 Avg: $326.2 Low: $300 Last Closed Price: $312.41

KRYS Stock Rating

Krystal Biotech stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 17 Strong Sell Sell Hold Buy Strong Buy

KRYS Price Target Upside V Benchmarks

TypeNameUpside
StockKrystal Biotech4.41%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-17
Avg Price Target-$300.00$295.86
Last Closing Price$312.41$312.41$312.41
Upside/Downside--3.97%-5.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26-101--11
May, 26-101--11
Apr, 26-101--11
Mar, 26-10---10
Feb, 26-11---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 05, 2026Evercore ISI$300.00$294.072.02%-3.97%
Feb 18, 2026Geulah LivshitsChardan Capital$323.00$282.6514.28%3.39%
Feb 17, 2026Roger SongJefferies$371.00$291.1027.45%18.75%
Jan 30, 2026Goldman Sachs$327.00$279.3417.06%4.67%
Jan 09, 2026H.C. Wainwright$310.00$248.9124.54%-0.77%
Oct 17, 2025Debjit ChattopadhyayGuggenheim$224.00$188.3318.94%-28.30%
Aug 22, 2025Chardan Capital$216.00$150.4943.53%-30.86%
Sep 11, 2024Dae Gon HaStifel Nicolaus$220.00$185.0018.92%-29.58%
Sep 02, 2024Alec StranahanBank of America Securities$205.00$195.125.06%-34.38%
Aug 12, 2024Gavin Clark-GartnerEvercore ISI$206.00$182.1713.08%-34.06%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 05, 2026Evercore ISIOutperformOutperformhold
May 05, 2026CitigroupBuyBuyhold
Mar 26, 2026Wolfe ResearchPeer Performinitialise
Feb 18, 2026CitigroupBuyBuyhold
Feb 17, 2026JefferiesBuyBuyhold
Jan 30, 2026Goldman SachsBuyBuyhold
Jan 09, 2026Cowen & Co.BuyBuyhold
Jan 09, 2026CitigroupBuyBuyhold
Jan 09, 2026H.C. WainwrightBuyBuyhold
Jan 06, 2026CitigroupNeutralBuyupgrade

Financial Forecast

EPS Forecast

$-5 $1 $7 $13 $19 $25 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.40$3.12$7.08---
Avg Forecast$-0.12$2.87$6.02$8.86$12.58$18.94
High Forecast$0.02$3.70$7.86$14.60$21.71$21.09
Low Forecast$-0.30$2.00$3.35$4.61$8.67$16.09
Surprise %-433.33%8.71%17.61%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.70M$290.51M$389.13M---
Avg Forecast$36.32M$291.49M$486.01M$709.09M$919.70M$1.26B
High Forecast$52.23M$295.81M$508.48M$729.99M$941.47M$1.37B
Low Forecast$24.67M$288.73M$451.36M$688.20M$897.93M$1.11B
Surprise %39.57%-0.33%-19.93%---

Net Income Forecast

$-50M $90M $230M $370M $510M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.93M$89.16M$204.83M---
Avg Forecast$-3.81M$79.02M$187.05M$320.43M$416.67M$525.62M
High Forecast$613.46K$102.56M$218.25M$405.05M$602.51M$585.29M
Low Forecast$-8.24M$55.47M$93.05M$128.06M$240.71M$446.55M
Surprise %-386.76%12.84%9.51%---

KRYS Forecast FAQ

Is Krystal Biotech stock a buy?

Krystal Biotech stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Krystal Biotech is a favorable investment for most analysts.

What is Krystal Biotech's price target?

Krystal Biotech's price target, set by 17 Wall Street analysts, averages $326.2 over the next 12 months. The price target range spans from $300 at the low end to $371 at the high end, suggesting a potential 4.41% change from the previous closing price of $312.41.

How does Krystal Biotech stock forecast compare to its benchmarks?

Krystal Biotech's stock forecast shows a 4.41% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Krystal Biotech over the past three months?

  • June 2026: 0% Strong Buy, 90.91% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 90.91% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 0% Strong Buy, 90.91% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Krystal Biotech’s EPS forecast?

Krystal Biotech's average annual EPS forecast for its fiscal year ending in December 2026 is $8.86, marking a 25.14% increase from the reported $7.08 in 2025. Estimates for the following years are $12.58 in 2027, and $18.94 in 2028.

What is Krystal Biotech’s revenue forecast?

Krystal Biotech's average annual revenue forecast for its fiscal year ending in December 2026 is $709.09M, reflecting a 82.22% increase from the reported $389.13M in 2025. The forecast for 2027 is $919.7M, and $1.26B for 2028.

What is Krystal Biotech’s net income forecast?

Krystal Biotech's net income forecast for the fiscal year ending in December 2026 stands at $320.43M, representing an 56.44% increase from the reported $204.83M in 2025. Projections indicate $416.67M in 2027, and $525.62M in 2028.